Literature DB >> 10789505

Severity-related molecular differences among nineteen strains of dengue type 2 viruses.

B D Pandey1, A Igarashi.   

Abstract

Comparative nucleotide sequencing was carried out on dengue type 2 virus (DEN-2) strains isolated from patients in Northeast Thailand during the epidemic season in 1993. The patients exhibited different clinical manifestations ranging from dengue fever (DF) to dengue haemorrhagic fever (DHF)/dengue shock syndrome (DSS). The results classified 19 DEN-2 strains into 3 subtypes according to nonsynonymous amino acid replacements. The strain isolated from a DSS patient eliciting secondary serological response belonged to subtype I, whereas 13 strains isolated from DHF patients with secondary response and 2 strains from DF patients with primary response belonged to subtype II. On the other hand, 3 strains isolated from DF cases evoking either primary or secondary response belonged to subtype III. These results suggest that subtype III virus infection could result in clinically milder manifestation irrespective of the serological response compared with subtype I or II viruses. The RNA secondary structure predicted for the 3' noncoding region showed 4 different structures (A, B, C, and D). The result also indicates that different subtypes of DEN-2 serotypes are circulating in a single epidemic in Thailand.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10789505     DOI: 10.1111/j.1348-0421.2000.tb02480.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  12 in total

1.  Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers.

Authors:  Richard M Kinney; Claire Y-H Huang; Becky C Rose; Andrew D Kroeker; Theo W Dreher; Patrick L Iversen; David A Stein
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 2.  Dengue virus life cycle: viral and host factors modulating infectivity.

Authors:  Izabela A Rodenhuis-Zybert; Jan Wilschut; Jolanda M Smit
Journal:  Cell Mol Life Sci       Date:  2010-04-06       Impact factor: 9.261

3.  Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels.

Authors:  Atsushi Yamanaka; Saori Kosugi; Eiji Konishi
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

4.  Nucleotide sequence and phylogenetic analyses of dengue type 2 virus isolated in the Dominican Republic.

Authors:  Saburo Anzai; Masako Fukuda; Yasushi Otsuka; Yuki Eshita
Journal:  Virus Genes       Date:  2004-10       Impact factor: 2.332

Review 5.  Microevolution and virulence of dengue viruses.

Authors:  Rebeca Rico-Hesse
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

Review 6.  Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease.

Authors:  Scott C Weaver; Nikos Vasilakis
Journal:  Infect Genet Evol       Date:  2009-02-13       Impact factor: 3.342

7.  The RNA Secondary Structure Analysis Reveals Potential for Emergence of Pathogenic Flaviviruses.

Authors:  Bibhudutta Mishra; Raviprasad Aduri
Journal:  Food Environ Virol       Date:  2021-10-25       Impact factor: 2.778

8.  Recent emergence of dengue virus serotype 4 in French Polynesia results from multiple introductions from other South Pacific Islands.

Authors:  Van-Mai Cao-Lormeau; Claudine Roche; Maite Aubry; Anita Teissier; Stéphane Lastere; Elise Daudens; Henri-Pierre Mallet; Didier Musso; John Aaskov
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

9.  Nosocomial transmission of dengue.

Authors:  Zsuzsanna Nemes; Gabriella Kiss; Edit P Madarassi; Zoltán Peterfi; Emoke Ferenczi; Tamas Bakonyi; Gabor Ternak
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

Review 10.  Dengue virus virulence and transmission determinants.

Authors:  R Rico-Hesse
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.